Day One®

We're for founders & operators. https://dayone.fm/shows

  1. 2d ago

    Clone Your Best People, Don't Replace Them: Natalie Ashes, CEO and Founder at WorkClone

    DESCRIPTION Every business has a few people who are commercially brilliant and close to impossible to replace. Natalie Ashes thinks the answer is to clone them, not to go and hire another one. In this episode of Building Tech Teams, James MacDonald sits down with Natalie Ashes, CEO and founder of WorkClone, an Australian AI company that builds clones of a business's best people, from their voice to how they actually work. They get into why clones amplify a team rather than replace it, why a clone still needs the real person behind it, and how a team of ten can work more like a team of eighty. It's a front-line view of AI adoption in Australian business, not the hype version. Natalie covers why around 88% of the executives her team surveyed admit to feeding private company data into AI models, why building voice AI in-house is harder than it looks, why off-the-shelf agents slip on guardrails, and what the first hires look like when you build an AI company from scratch. They also get into the go-to-market role that is evolving out of the BDM, what the future of work looks like when every team is a mix of people and clones, and why Natalie says Australia should own its AI future instead of renting it. CHAPTERS 00:00 Cold open: 10 people, 100 headcount 01:28 Nat Clone previews the episode 03:32 What WorkClone does: cloning your unicorns 04:46 Amplification, not replacement 06:15 Shadow AI and the trust problem in Australia 08:44 Start small: the Clone Father and one or two workflows 10:37 Build or buy? When the CTO says "we'll do it ourselves" 13:39 Building is easy, supporting it is hard 15:30 The couch company and the bedtime story 16:25 Security, data hosting and the risks nobody talks about 17:19 One clone, 44 sub-clones and why 98% isn't good enough 19:36 What if the big labs build this? 21:35 FDEs, channels and clones with memory 23:28 Just because you can build it doesn't mean you should 24:33 Cloning real people: jobs, IP and personality 26:40 Will the clone beat the original? 29:20 Amplify the team or shrink it? 31:08 From CMO to AI founder 34:03 How to catch up: get your hands dirty 35:17 Careers, creatives and the mid-level squeeze 38:31 Kids, careers and finding your passion 40:10 First hires and the rise of go-to-market 43:30 Is Australia behind on AI? The air conditioning test 46:31 ROI, token costs and starting small 48:57 Voice AI 12 months on: emotion and speech to speech 50:17 The team maths: 10 people vs 100 53:03 Do clones say they're clones? 54:45 Dating your clone and the human plus clone workforce 56:35 Owning Australia's AI future 57:10 James's wrap up ABOUT THE GUEST Natalie Ashes is the CEO and founder of WorkClone, an Australian AI company that builds clones of a business's top performers, covering their voice and their ways of working. She comes from a marketing background, most recently as CMO at Novated Lease Australia, and moved into AI after building a clone of herself called Marketing Nat. LINKS Natalie Ashes, WorkClone · LinkedIn: https://www.linkedin.com/in/natalie-ashes-479ba627/ James MacDonald, NTP Talent · LinkedIn: linkedin.com/in/jamesmacdonaldau · Site: ntptalent.com.au Hosted by James MacDonald, Managing Director of NTP Talent. Building Tech Teams is produced by Day One®, trusted partners in the technology space and the production partner behind Blackbird Ventures' Wild Hearts. Sister shows include First Cheque, Oversubscribed and In The Blink of AI. Episodes are cross-promoted across the network.

    Clone Your Best People, Don't Replace Them: Natalie Ashes, CEO and Founder at WorkClone
  2. 2d ago

    Physical AI Is 10x Bigger Than Software: How 8 Robotics Founders Are Rebuilding Australia

    Episode Summary A pipe-crawling robot that maps water, energy and mining networks in 3D. A gripper that can feel how hard to hold something, solving one of the biggest gaps in robotics today. A modular drone with payloads that click together like LEGO. And what Freesia Gaul calls a PS4 remote for your hand, letting you feel objects inside video games. This episode of Oversubscribed was recorded live at Build Australia HQ in Sydney, with founders who brought their hardware to the table. Joining Brendan Hill are Samuel Gonzalez of Peregrine Dynamics, Freesia Gaul of On Zero, Patrick Bellamy of Kronus, Antoine Nguyen of Dreamscale Labs, Shyeon Delnawaz of Puralink Robotics, Heba Khamis of Contactile, Joe Harris of Alloy and Oleg Sushkov of Reimagine Robotics. They get into why they chose to build something this hard, how they handle adversity, and what raising for hard tech looks like now that every VC has a physical AI thesis. Then the biggest question of the episode: how can Australia start building stuff again and establish our own ‘El Segundo’. Time Stamps 00:00 Cold Open: Robot Demos, Live in the Room 01:23 Welcome to Build Australia HQ & Founder Intros 06:40 Sponsor: Mighty Partners 07:15 Live Demos: PureLink's Ferret, Contactile's Tactile Grip & Peregrine's Drone 22:34 Sponsor: Vanta 24:04 Dreamscale Labs, Cronus & Alloy on Building the Hardest Tech 30:42 Sydney, London & SF: Where These Founders Are Building From 39:28 Sponsor: Ten13 39:55 Why Choose the Hardest Possible Route (And How to Survive It) 57:41 "Turbo Cockroach": Adversity, Resilience & the Alloy Raise 1:05:17 How Fundraising for Hard Tech Has Changed 1:15:14 Capital Efficiency: Learning How to Spend Money Well 1:22:14 Robotics in YC & Raising in a Hot Market 1:23:41 Vision for Australia: The Next 20 to 30 Years 1:31:08 Australia's Identity Problem: Lifestyle vs Ambition 1:37:27 Closing Thoughts & the Robot Party Oversubscribed is proudly supported by our sponsor Vanta 🦙 and Mighty Partners 💪 Vanta is the all-in-one solution for startups to become compliant quickly and build a security foundation with ease. Startup customers get $1000 off Vanta at https://www.vanta.com/oversubscribed ___ Mighty Partners is Australia's leading venture debt provider for high-growth software companies. Venture debt gives founders access to growth capital while preserving equity, extending runway and creating greater flexibility between funding rounds. It's designed for ambitious technology businesses that want to keep building without giving away more ownership than necessary. Trusted by companies including BuildPass, Deckard Technologies and Pearler, Mighty helps founders scale on their own terms. Learn more about venture debt and how it can support your next stage of growth at https://www.mightypartners.com.au/oversubscribed The Day One Network Oversubscribed is part of Day One, the podcast network dedicated to founders, operators & investors. Please note that the content here is for informational purposes only; should NOT be taken as legal, business, or investment advice or be used to evaluate any investment or financial product. Brendan Hill is an investor in Alloy Robotics, Puralink, Peregrine Dynamics, Dreamscale Labs and Kronus. About the Host: Brendan Hill is a Venture Partner at TEN13 and an angel investor in Australia’s fastest-growing startups, including Everlab, Heidi Health, Relevance AI and Instant. If you are interested in finding out more about angel investing, connect with Brendan on LinkedIn: https://www.linkedin.com/in/itsbrendanhill/

    Physical AI Is 10x Bigger Than Software: How 8 Robotics Founders Are Rebuilding Australia
  3. 5d ago

    Inside the $250M Aussie HealthTech Fund

    Many investors avoided antimicrobial resistance. Then Eli Lilly agreed to pay up to US$780 million for LimmaTech Biologics, a vaccine developer backed by Tenmile. Dr Steve Burnell explains what a contrarian thesis, pharma's growing appetite for early assets and Australia's funding gap mean for the next wave of biotech. This is the one episode you want to listen to if you want to know where Biotech is going in 2026 - what matters, where capital is moving, what investors are actually looking for and where Australia fits in all that. Join us as we deep dive into this $250M funds formation, thesis and operations built with expertise from decades across the US and Aussie health system. Emily Casey, founder and Director of What the Health, is joined by Dr Steve Burnell, Managing Director of Tenmile, the Tattarang-owned health technology investment business launched with an initial A$250 million allocation. Dr Burnell is Managing Director of Tenmile and Chair of its Investment Committee. Before Tenmile he managed a global business, led M&A and established a new informatics and real-world data business at Roche-Genentech in the US. He remains a senior strategic advisor to Minderoo Foundation, where he led large initiatives in COVID-19, cancer and ocean genomics. He holds a BSc (Hons) in Biology and a PhD in Population Biology from the University of Sydney. Together they unpack: Where Australia's capital gap really sits: late pre-clinical and early clinical stages, where rounds run to tens of millionsWhy pharma is moving earlier, and what the patent cliff means for dealmakingWhy Dr Burnell says antimicrobial resistance was a hard sell for investors, and what changed before Lilly's LimmaTech dealThe "who pays?" test every founder should pass before pitching, with Heidi Health as a case studyHow Tenmile screens by theme, tests the science and the team, then moves through diligence and syndicationThe founder mistakes to avoid, including how to approach NDAsTenmile's investment themes beyond antimicrobials: women's health, mental health, oncology and AI in drug discoveryWhere he expects medicine to head by 2035: personalised mRNA medicines and a deeper understanding of the immune system Chapters 00:00 Why this conversation, and a path from marine biology to Roche 08:30 What Tenmile is and how the Forrest backing came about 14:20 Australia's valley of death and where the capital gap really sits 19:56 What would fix it: coordinated capital, companies that stay onshore, US investors 26:47 Is biotech overheating? AI, the patent cliff and pharma buying earlier 31:56 The contrarian bet: antimicrobial resistance and the LimmaTech exit 36:09 Why founders must answer "who pays?" 42:15 Where the next breakthroughs are: personalised mRNA, AI and drug discovery 47:33 Tenmile's investment themes and what comes next for Tenmile 54:33 How Tenmile makes an investment, and the founder mistakes to avoid 1:02:20 Healthcare in 2035, and lessons from a career in venture 1:10:38 Rapid fire Links and resources What the Health: https://whatthehealth.io/ Tenmile Ventures: https://www.tenmile.com/ Tenmile portfolio: https://www.tenmile.com/portfolio Tenmile team, including Dr Steve Burnell: https://www.tenmile.com/about-us Mentioned in the episode Lilly to buy three vaccine developers, including LimmaTech (BNN Bloomberg): https://www.bnnbloomberg.ca/business/2026/05/26/lilly-to-buy-three-vaccine-developers-for-nearly-us4-billion-in-infectious-disease-push/Goodwin on LimmaTech's acquisition by Lilly, listing its backers: https://www.goodwinlaw.com/en/news-and-events/news/2026/05/announcements-lifesciences-ma-goodwin-advises-limmatech-biologicsMerck and Moderna report positive Phase 3 melanoma results for intismeran (AJMC): https://www.ajmc.com/view/moderna-merck-mrna-cancer-vaccine-succeeds-in-late-stage-trialThe pharma patent cliff explained (American Action Forum): https://www.americanactionforum.org/insight/the-patent-cliff-and-the-drug-markets-innovation-cycle/Heidi Health's Series C (MobiHealth News): https://www.mobihealthnews.com/news/heidi-health-garnered-340m-reaches-900m-valuationLumos Diagnostics and Tenmile (Stockhead): https://stockhead.com.au/health/alive-and-kicking-lumos-diagnostics-attracts-twiggy-forrest-as-cornerstone-holder-in-10m-raiseAdvanCell's A$452 million Series D (Forbes Australia): https://www.forbes.com.au/covers/innovation/brisbane-biotech-advancell-just-raised-a-record-450-million/ Subscribe for more conversations cutting through the noise in health technology, biotech and healthcare innovation. What the Health is brought to you in partnership with Tenmile Ventures. Emily Casey also works part time at Tenmile, where she leads community and partnerships. What the Health is part of Day One Network: https://dayone.fm/ #HealthTech #Biotech #VentureCapital #HealthcareInnovation

    Inside the $250M Aussie HealthTech Fund
  4. Nov 3

    Why Investors Keep Saying No (And What to Do About It) | Justin Wastnage from Vloggi

    Episode Summary Justin Wastnage is the founder and CEO of Vloggi, a platform that transforms everyday mobile phone footage into trusted, structured, legally owned video assets for businesses and enterprises. What started as a tool for tourism boards to crowdsource location content has evolved, through COVID, multiple pivots, and years of customer-funded development, into an infrastructure layer that verifies, structures and processes video for some of the world's most compliance-heavy industries. In this episode, Justin joins Alan to talk honestly about the challenges of pitching a business that investors think they already know. Vloggi has worked with Major League Baseball, Netflix, the NSW Government, and Google Ads, yet raising in Australia remains stubbornly difficult. Alan digs into why that is and what Justin can do about it, from repositioning the pitch, to rebranding, to putting someone else in the room. If you're a founder who has pivoted hard but can't shake what investors remember about your old story, this one is for you. Time Stamps 00:00 – Intro 02:03 – Meet Justin Wastnage and the origins of Vloggi 04:57 – What Vloggi does: video as content, data and evidence 07:11 – What changed with synthetic AI video and why it matters now 09:00 – The pivot story: from tourism boards to enterprise compliance 12:35 – Bootstrapping and the team behind Vloggi 13:03 – The current raise: $800k to bring the enterprise product to market 17:03 – How Vloggi verifies that uploaded video is authentic, not AI-generated 19:33 – Commercial model: per project vs ongoing enterprise licensing 22:31 – Why Vloggi wants to be infrastructure, not a consumer brand 24:48 – Alan's challenge: how to reposition when investors think they know your old story 29:08 – Should you rebrand? The case for and against 32:26 – Pitch deck strategy: teaser first or full deck upfront? 35:23 – Alan pitches Vloggi back to Justin the way he'd do it 38:51 – The airline use case and how to open with one vertical then go broad Resources - Ask Alan a Question – https://speakpipe.com/pickmybrain - More from Alan Jones – https://www.startupfoundercoach.com The Day One Network Pick My Brain is part of Day One, the podcast network dedicated to founders, operators & investors. To learn more, join our newsletter (https://dayone.fm/newsletter) to be notified of new and upcoming shows. Day One helps founders and startup operators make better business decisions more often. Follow our socials Linkedin: / dayonefm Instagram: / dayone.fm TikTok: / dayone.fm

    Why Investors Keep Saying No (And What to Do About It) | Justin Wastnage from Vloggi
  5. Oct 31

    Building A Flywheel That Cultivates Talent

    Harry Uffindell has spent his career hiring the kind of people you don’t need to manage. From law, to consulting, to founding his own startup, to 5.5 years as CPO at Partly, and now building at Manifest - Harry has seen what happens when you trade quality for speed. In this episode of the FNDN Series, Harry joins Matt McFarlane to share why great hiring starts before the JD goes live, how he stole Amazon’s Bar Raiser system for a Kiwi startup, and why his filter for 10x talent is simple: self-guided missiles. Matt and Harry dive into the AI-enabled 45-minute Role Launch process that saves you months of wheel-spinning, the post-loop debrief with silent reads that protects talent density, and the real cost of putting a good bum in a seat. They also unpack talent cultivation - how to build a 12-24 month tsunami of great people, why he partnered with top university societies to create a hiring flywheel, and the billboard he’d put in San Francisco to bring Aussie and Kiwi talent home. Harry also reflects on why the top 1% of grads right now are mind-blowing, why years of experience is a broken proxy for ability, and why having a non-traditional background in People might be his biggest superpower. Episode Chapters 00:00 – Intro - Welcome Harry to the FNDN Series 02:15 – How do you actually define top talent / 10x / A-players? 05:30 – The Role Launch Process: Why speed now elongates your hiring later 08:45 – Building a Claude Skill to fast-track the process for busy hiring managers 11:50 – Speed vs. Intentionality: How to get the business to accept diligence upfront 15:20 – The 50-interview junior designer and what great actually looks like 18:40 – The Bar Raiser: Stealing Amazon’s most frustrating, most impactful process 22:10 – Inside the post-loop debrief: silent reads, scores, and handling amber flags 26:35 – The vibe check: Are you excited to tap people on the shoulder? 29:30 – B-players hire C-players: When threat is actually opportunity 33:15 – Self-guided missiles: Harry’s filter for true end-to-end ownership 37:40 – Ghost jobs, 300 AI applications a day, and how to find the best in the country 41:05 – The care test: How Harry interviews for obsession 44:20 – Talent Cultivation: Playing the long game and building your tsunami 47:30 – Should you hire the person or the role? It’s stage dependent 52:00 – Referrals and the question: Who would you follow if they started a company? 55:40 – The uni society flywheel: Hiring the 2-3 go-to people in each cohort 59:10 – The San Francisco billboard to bring talent back to AU/NZ 01:02:30 – AI-native grads, equity, and why top grads want to control their destiny 01:06:45 – The AU/NZ problem: Why we can’t just trade the same talent pool 01:11:30 – Why scaling from 200 to 800 means we need to create new talent 01:14:00 – Law to CPO: Why outsiders make the biggest step changes Resources 🚀 Partly: https://www.partly.com/ - where Harry spent 5.5 years scaling the team 🛠️ Manifest: https://www.manifest.build/ - where Harry is building now https://fndnseries.fndn.com.au/podcast

    Building A Flywheel That Cultivates Talent
  6. Oct 26

    Mark Deacon's Marketing Hub: AI Revenue Engine

    Canibuild's sales team used to record personalised prospect videos by hand. Each one took 15 to 20 minutes, so reps did them in bursts, when they had spare time. Mark Deacon replaced that routine with a system that scripts, produces and tracks the videos, and he opens his screen to show every step. Mark is Chief AI Officer at Canibuild. He has spent his career leading sales, marketing and customer success teams, and he does not write code. He built the Marketing Hub, an internal platform where Canibuild's teams serve themselves instead of queuing for engineering. The outreach video tool is the centrepiece. A rep enters a prospect's website, or imports a list from a CSV or a HubSpot segment. The system scrapes the site, writes a script and produces a video of about a minute. It opens on the prospect's own website, then moves into the Canibuild product and ends on a call to action. Each video features an AI avatar of the account's real rep, with a HeyGen face and an ElevenLabs voice. Mark said reps supplied short recordings to set these up, and a personalised landing page goes out with the video. Mark was direct about the results. By his account, conversion is roughly on par with videos reps record themselves. The gain is volume: a handful a month before, and potentially a thousand now, at about $4 a video. Video watches trigger Slack alerts and HubSpot tasks; demo bookings create deals, so reps do not need to live in the Marketing Hub. The build-versus-buy split is useful. Mark said Canibuild's tools split roughly 50/50. It buys anything customer-facing that needs near-perfect uptime, such as its 11x AI SDR. It builds internal tools where a day of downtime is an inconvenience, not a crisis. He also showed an early version of a newsletter builder. It reads the engineering team's Jira roadmap and industry news, scores what matters for a chosen segment, and publishes through HubSpot. Mark noted that it still needs a person to pick articles and images. Automatic segment-by-segment sending is the next step. The second half widens out. Every Canibuild tool starts as a flow tested in the terminal, then gets an interface so the team can run it without waiting on Mark. Staff build dashboards and apps in VS Code using shared skills. Those skills apply templates, scan for leaked API keys, push to a central GitHub and register each tool on a master dashboard, so nothing disappears when its builder leaves. Mark described his role as enablement. He wants the people with domain expertise to build, inside guardrails, without turning his team into a new engineering queue. His advice for beginners: start with Claude Code or Codex in the terminal, tie the first build to a real business problem, and keep humans on the first 20 per cent (thinking) and the last 20 per cent (review) of the work. About Mark Deacon Mark Deacon is Chief AI Officer at Canibuild. He is a revenue leader whose background spans sales, marketing, customer success and go-to-market strategy. He runs a growing set of internal AI tools for Canibuild's teams and posts about what he is building on LinkedIn. Chapters 00:00 Cold open and intro 01:50 Why manual Loom videos did not scale 04:20 Terminal first, then a self-serve interface 05:18 From prospect website to scripted video 07:06 AI avatars, cloned voices and landing pages 12:15 Conversion parity, volume and cost per video 14:35 Watches become Slack alerts, HubSpot tasks and deals 17:43 Build versus buy: the AI SDR and enrichment 20:10 A revenue leader building without engineers 22:45 Newsletter builder fed by the product roadmap 27:22 Guardrails so everyone can build 32:22 Chief AI Officer: enablement, not a new bottleneck 38:58 Rapid fire 43:35 How to start, and the 20/60/20 rule Links and resources Mark Deacon on LinkedIn: https://www.linkedin.com/in/markpdeacon/ Canibuild: https://canibuild.com/ HubSpot: https://www.hubspot.com HeyGen: https://www.heygen.com ElevenLabs: https://elevenlabs.io 11x: https://www.11x.ai FullEnrich: https://fullenrich.com Astro: https://astro.build About the host Zachary King is the founder of Works, where he installs AI into how Australian companies operate. He has worked at the commercial pointy end of AI for almost twenty years and runs his own company largely from the command line. About the show Operator AI is the show where real operators open their screens and show exactly how they run the real parts of their business with AI. The real stack, not the hype. If you want AI installed into how your business actually operates, learn more at https://workshq.com.au/ or book a time with Zachary King at https://savvycal.com/Zachary-King/zac-at-works-30. Operator AI is part of Day One Network, the podcast and media network from W2D1 Media: https://dayone.fm/.

    Mark Deacon's Marketing Hub: AI Revenue Engine
  7. Oct 17

    Stop Automating Away the Moments That Matter

    Danny Seals has advised some of the most complex People teams in the world — big pharma, banking, and large-scale consultancies — and right now he's hearing the same thing from senior leaders everywhere: "I'm the most senior I've ever been in my career, and I feel like I'm the dumbest person. I'm burnt out. My experience has limited value because the instant answer is put it through ChatGPT." In this episode of the FNDN Series, Matt McFarlane sits down with Danny, founder of Knot, a People experience advisory, and author of The Insightful Innovator, to unpack the big addiction to efficiency that's sweeping People and Culture. Danny calls it Minutes vs. Moments — we’re obsessed with saving 10 minutes here and there, but we’re removing all the moments that actually build trust, loyalty and high-performing teams. From banking chatbots named Aura that add friction instead of removing it, to bereavement leave being handled by a bot, to HR teams vibe-coding their entire tech stack in Claude, we explore what should be automated and what should never be touched. Matt and Danny also get into product-led thinking for People teams, his SPIES framework (Subscription, Products, Interactions, Experiences, Services), why IKEA turned customer service reps into digital interior designers instead of making them redundant, what X-shaped people do differently from T-shaped specialists, and how his Team MRI diagnostic — run over 100 times — helps teams see where experience is really leaking. If you're building a People function in the age of AI, this is the filter you need before you automate anything. Episode Chapters 00:00 – Intro 01:08 – Welcome to the pod with Danny Seals 02:40 – Where is People experience practice today? 03:03 – The AI & efficiency addiction: why senior leaders feel burnt out 04:49 – Where AI pressure is really coming from in HR 05:53 – Minutes vs. moments: the framework 07:30 – Moments that matter that AI should never touch 09:30 – SPIES, banking apps, and situational design 13:00 – When fraud happens: why white-glove human service is becoming a premium 19:00 – Product thinking vs. "work as a product" — language matters 28:00 – SPIES explained: hardware is strategy, software is capability 32:00 – T-shaped vs M-shaped vs X-shaped people 37:00 – Hiring for curiosity: what X-shaped people do day-to-day 41:00 – From crime scene investigation to audience insight: what "leakage" tells you 46:00 – The rise of the People engineer and what IKEA got right 50:00 – Vibe-coding your HR stack and the redundancy-to-rehire trap 54:00 – The future of the HRBP role: capability vs. job description 60:00 – The Team MRI: diagnosing 12 traits of high-performing teams 67:22 – One idea to steal: problem valuation — talk in feelings and figures 🧠 Danny Seals – People Experience expert, founder of Knot and Knot Another Newsletter 📚 The Insightful Innovator – Book by Danny Seals on People experience 🏢 IKEA Case Study – Reskilling customer service reps into digital interior designers https://fndnseries.fndn.com.au/podcast

    Stop Automating Away the Moments That Matter
  8. Oct 14

    Longevity BS, Breakthroughs and What Comes Next

    In Part Two of my conversation with Dr Steven Lu, Everlab’s co-founder and Chief Medical Officer, we unpack what’s actually worth measuring, which treatments show real promise, what’s still experimental and what the future of preventative healthcare could look like. And why, when it comes to optimising our health, we should be problem-centric, not solution-centric. We dive into: What keeps Steven up at night as Everlab grows and expands internationally.What’s actually worth measuring: From Lp(a), a genetically influenced cardiovascular risk marker, to body composition, and the tests Steven believes deserve more attention.GLP-1s, breakthrough drugs or misunderstood medicine? Their potential, the risks of poor dosing and inadequate support, and why protecting muscle and bone health matters.The peptide boom: What’s backed by evidence, the safety and quality concerns, and why Steven isn’t ready to inject them himself. Yet.Being problem-centric, not solution-centric: Why chasing the latest tests, treatments and biohacks isn’t necessarily the best approach to better health.AI and the future of primary care: How Everlab’s Concierge is bringing AI into healthcare while keeping clinicians in the loop.The next frontier of preventative medicine: Pharmacogenetics, personalised care and emerging Alzheimer’s blood tests.Hype or worth it? Steven’s rapid-fire take on full-body MRIs, continuous glucose monitors, wearables, NAD+ infusions and creatine, plus the health habits he thinks are overhyped and underappreciated. Chapters 00:00 Preview: what's real in longevity 01:12 What keeps Steven up at night: leading Everlab through uncharted waters 03:00 What's worth measuring: Lp(a) and body composition 05:28 GLP-1s: what works, and what goes wrong without support 12:13 Peptides: the evidence gap and his "would I take it myself?" test 18:28 Be problem-centric, not solution-centric 22:41 Pharmacogenetics, tailored care and the public system's role 24:03 AI in primary care: keeping a clinician in the loop 27:55 The pTau217 Alzheimer's blood test and what Everlab is studying next 31:06 Rapid fire: MRI, CGMs, wearables, NAD+ and creatine 38:59 Lightning round: favourite emoji, overhyped and underhyped 41:40 Family, where to find Everlab, and thanks Links and resources What The Health: https://whatthehealth.io/ Everlab: https://www.everlab.com.au/ Dr Steven Lu at Everlab: https://www.everlab.com.au/doctors Tenmile Ventures: https://www.tenmile.com/ Mentioned in the episode: Everlab Concierge product update (the AI health assistant, Eva, that Steven describes): https://www.everlab.com.au/post/introducing-everlab-conciergeKFF Health Tracking Poll, November 2025 (12% of US adults say they currently take a GLP-1 drug; 18% have ever taken one): https://www.kff.org/health-costs/poll-1-in-8-adults-say-they-are-currently-taking-a-glp-1-drug-for-weight-loss-diabetes-or-another-condition-even-as-half-say-the-drugs-are-difficult-to-afford/TGA, concerns about unapproved peptide products (background to the peptide discussion): https://www.tga.gov.au/news/media-releases/concerns-regarding-public-health-risks-associated-unapproved-peptide-productsRACGP newsGP, TGA warning on unapproved peptides (April 2026): https://www1.racgp.org.au/newsgp/professional/tga-issues-warning-against-unapproved-peptidesMSAC Application 1736 (the proposal to list Lp(a) testing on the MBS; outcome pending): https://www.msac.gov.au/applications/1736RACGP submission on MSAC Application 1736 (October 2022; opposes the listing): https://www.racgp.org.au/advocacy/reports-and-submissions/view-all-reports-and-submissions/2022-reports-and-submissions/msac-application-1736-lipoprotein-a-testing-asAusDoc, Australian Atherosclerosis Society backs the proposed Lp(a) MBS items: https://ausdoc.com.au/specialist-update/cardiologists-back-expanded-lipoproteina-testing-for-at-risk-patientsAustralian Atherosclerosis Society, patient brochure on elevated lipoprotein(a): https://www.athero.org.au/fh/wp-content/uploads/Lpa-brochure.pdfMedical Republic on the pTau217 Alzheimer's blood test (Roche test authorised in Australia; the Health Minister's comments): https://medicalrepublic.com.au/mark-butler-and-the-holy-grail-of-dementia-tests/127796Axios on OpenAI's report on ChatGPT health use (January 2026; more than 40 million people ask daily): https://axios.com/2026/01/05/chatgpt-openai-health-insurance-acaNews 12 New York on the death of a woman after an NAD+ infusion at a Bronx wellness centre (the case Steven refers to in the rapid-fire round): https://bronx.news12.com/prosecutors-unauthorized-nad-iv-infusion-led-to-womans-death Subscribe for more conversations cutting through the noise in health technology, biotech and healthcare innovation. What the Health is brought to you in partnership with Tenmile Ventures. What the Health is part of Day One Network: https://dayone.fm/ #HealthTech #Longevity #PreventativeHealth #AIinHealthcare

    Longevity BS, Breakthroughs and What Comes Next

Trailers

About

We're for founders & operators. https://dayone.fm/shows

More From Day One